Efficacy of Polatuzumab, Bendamustine and Rituximab in patients with relapsed/refractory mantle cell lymphoma- A single center phase II trial

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-518704-41-00

Acronym

Pola_R_Benda

Enrollment

Registered

2024-12-10

Start date

2023-07-12

Completion date

2025-06-17

Last updated

2024-12-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Mantle cell lymphoma

Brief summary

Safety, response assessment and duration

Detailed description

none

Interventions

DRUGMabThera 500 mg concentrate for solution for infusion

DRUGPolivy 30 mg powder for concentrate for solution for infusion.

DRUGBendamustin Accord 2

DRUG5 mg/ml Pulver für ein Konzentrat zur Herstellung einer Infusionslösung

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Safety, response assessment and duration	—

Secondary

Measure	Time frame
none	—

Countries

Austria

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026